Extended indication Rinvoq is indicated for the treatment of non radiografic active ankylosing spondylitis in adult pati
Therapeutic value No estimate possible yet
Total cost 2,864,000.00
Registration phase Registration application pending

Product

Active substance Upadacitinib
Domain Chronic immune diseases
Reason of inclusion Indication extension
Main indication Rheumatism
Extended indication Rinvoq is indicated for the treatment of non radiografic active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy
Proprietary name Rinvoq
Manufacturer abbvie
Portfolio holder abbvie
Mechanism of action JAK tyrosine kinase inhibitor
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date January 2022
Expected Registration August 2022
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Current treatment options Na falen NSAID zijn TNFi of anti-IL17A geregistreerd voor deze indicatie
Therapeutic value No estimate possible yet
Substantiation De therapeutische waarde is nog niet bekend, maar dit geneesmiddel zal indien effectief waarschijnlijk ingezet worden na falen op anti-TNF of anti-IL17 therapie.
Frequency of administration 1 times a day
Additional comments NCT04169373

Expected patient volume per year

Patient volume

< 250

Market share is generally not included unless otherwise stated.

References Landewé en Van der Heijde. Ned Tijdschr Geneeskd. 2011(1); Expert opinie(2);
Additional comments De prevalentie van nrSpA wordt ingeschat tussen de 0,3%-0,4% (1). Ongeveer 50% van de patiënten wordt behandeld met een biological (2) . De inschatting is dat het met name gebruikt gaat worden na falen op een TNF-blokker en dat er ongeveer 450 patiënten voor in aanmerking zullen komen.

Expected cost per patient per year

Cost 11,456.00
References G-standaard
Additional comments Gebaseerd op kosten van andere behandelingen met Rinvoq. AIP 15mg : €879 per pack 28 tabletten, €11.456 per jaar

Potential total cost per year

Total cost

2,864,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

Off label use No

Indication extension

Indication extension Yes
Indication extensions Crohn's disease; Ulcerative colitis; Hidradenitis suppurativa

Other information

There is currently no futher information available.